Literature DB >> 20528472

Palivizumab-resistant human respiratory syncytial virus infection in infancy.

Ortwin Adams1, Linda Bonzel, Alexander Kovacevic, Ertan Mayatepek, Thomas Hoehn, Markus Vogel.   

Abstract

Palivizumab-resistant respiratory syncytial virus was isolated from an infant treated with palivizumab. A stable mutation at codon 276 led to a nearly complete resistance to palivizumab. Additional studies revealed a second mutation at codon 272. Further passage of the virus led to a complete loss of binding of palivizumab.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20528472     DOI： 10.1086/653534

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  27 in total

1.  Cross-neutralization of four paramyxoviruses by a human monoclonal antibody.

Authors:  Davide Corti; Siro Bianchi; Fabrizia Vanzetta; Andrea Minola; Laurent Perez; Gloria Agatic; Barbara Guarino; Chiara Silacci; Jessica Marcandalli; Benjamin J Marsland; Antonio Piralla; Elena Percivalle; Federica Sallusto; Fausto Baldanti; Antonio Lanzavecchia
Journal:  Nature       Date:  2013-08-18       Impact factor: 49.962

2.  Respiratory syncytial virus prevention in children with congenital heart disease: who and how?

Authors:  Nam Kyun Kim; Jae Young Choi
Journal:  Korean J Pediatr       Date:  2011-05-31

3.  NEP: web server for epitope prediction based on antibody neutralization of viral strains with diverse sequences.

Authors:  Gwo-Yu Chuang; David Liou; Peter D Kwong; Ivelin S Georgiev
Journal:  Nucleic Acids Res       Date:  2014-04-29       Impact factor: 16.971

Review 4.  Passive immune neutralization strategies for prevention and control of influenza A infections.

Authors:  Jianqiang Ye; Hongxia Shao; Daniel R Perez
Journal:  Immunotherapy       Date:  2012-02       Impact factor: 4.196

5.  Identification of nucleolin as a cellular receptor for human respiratory syncytial virus.

Authors:  Farnoosh Tayyari; David Marchant; Theo J Moraes; Wenming Duan; Peter Mastrangelo; Richard G Hegele
Journal:  Nat Med       Date:  2011-08-14       Impact factor: 53.440

6.  Reverse genetics systems for contemporary isolates of respiratory syncytial virus enable rapid evaluation of antibody escape mutants.

Authors:  Wendy K Jo; Alina Schadenhofer; Andre Habierski; Franziska K Kaiser; Giulietta Saletti; Tina Ganzenmueller; Elias Hage; Sibylle Haid; Thomas Pietschmann; Gesine Hansen; Thomas F Schulz; Guus F Rimmelzwaan; Albert D M E Osterhaus; Martin Ludlow
Journal:  Proc Natl Acad Sci U S A       Date:  2021-04-06       Impact factor: 11.205

Review 7.  Neutralizing epitopes of RSV and palivizumab resistance in Japan.

Authors:  Koichi Hashimoto; Mitsuaki Hosoya
Journal:  Fukushima J Med Sci       Date:  2017-09-01

8.  Escape from neutralization by the respiratory syncytial virus-specific neutralizing monoclonal antibody palivizumab is driven by changes in on-rate of binding to the fusion protein.

Authors:  John T Bates; Christopher J Keefer; James C Slaughter; Daniel W Kulp; William R Schief; James E Crowe
Journal:  Virology       Date:  2014-03-03       Impact factor: 3.616

9.  GS-5806 Inhibits a Broad Range of Respiratory Syncytial Virus Clinical Isolates by Blocking the Virus-Cell Fusion Process.

Authors:  Michel Perron; Kirsten Stray; April Kinkade; Dorothy Theodore; Gary Lee; Eugene Eisenberg; Michael Sangi; Brian E Gilbert; Robert Jordan; Pedro A Piedra; Geoffery L Toms; Richard Mackman; Tomas Cihlar
Journal:  Antimicrob Agents Chemother       Date:  2015-12-14       Impact factor: 5.191

10.  Residue-level prediction of HIV-1 antibody epitopes based on neutralization of diverse viral strains.

Authors:  Gwo-Yu Chuang; Priyamvada Acharya; Stephen D Schmidt; Yongping Yang; Mark K Louder; Tongqing Zhou; Young Do Kwon; Marie Pancera; Robert T Bailer; Nicole A Doria-Rose; Michel C Nussenzweig; John R Mascola; Peter D Kwong; Ivelin S Georgiev
Journal:  J Virol       Date:  2013-07-10       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.